Multi-omics profiling reveals divergent biology and liver microenvironment in HCC of metastatic and de novo origin [0.03%]
多组学谱分析揭示肝转移癌和原发肝癌的生物学特性和微环境差异
Gina F Boot,Fabian Haak,Mairene Coto-Llerena et al.
Gina F Boot et al.
KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis [0.03%]
KDM5B驱动的葡萄糖代谢重编程通过乳酸/ hnRNPA1丙酰化/ AR-V7轴促进前列腺癌耐药性形成
Rui Sun,Yong Huang,Hao He et al.
Rui Sun et al.
Micropeptide YG-6 encoded by exosomal LINC01123 derived from highly migratory ovarian cancer cells promotes tumor progression [0.03%]
由高迁移卵巢癌细胞衍生的长链非编码RNA LINC01123编码的微肽YG-6促进肿瘤进程
Han Lei,Zhengwei Zhou,Chengyuan Li et al.
Han Lei et al.
LncRNA NEAT1 promotes immunosuppression in gastric cancer under endoplasmic reticulum stress by maintaining the M6A methylation of SEMA3A in CAFs [0.03%]
长链非编码RNA NEAT1通过维持癌相关成纤维细胞中SEMA3A的m6A甲基化在内质网应激下促进胃癌免疫抑制作用
Youqin Xu,Rui Xu,Zixin Chen et al.
Youqin Xu et al.
Autophagy in cancer-associated fibroblasts: its role in gastrointestinal cancers [0.03%]
癌症相关成纤维细胞的自噬在胃肠道肿瘤中的作用研究进展
Vaishnavi Kuppala,Hasini Chintapudi,Gopalaiah Kovuru et al.
Vaishnavi Kuppala et al.
Correction: N6‑methyladenosine‑modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14‑dependent manner in renal cell carcinoma [0.03%]
纠正：N6-甲基腺苷甲基化的TRAF1通过METTL14依赖性调节凋亡和血管生成促进肾细胞癌对舒尼替尼的耐药性
Yuanlei Chen,Zeyi Lu,Chao Qi et al.
Yuanlei Chen et al.
Published Erratum
Molecular cancer. 2026 Mar 3;25(1):56. DOI:10.1186/s12943-026-02596-8 2026
m6A-dependent translation of circPICALM encodes a novel metastasis-promoting oncoprotein in intrahepatic cholangiocarcinoma [0.03%]
胆管癌中依赖m6A的circPICALM翻译编码促进转移的新型致癌蛋白
Hui Li,Sheng Wang,Fengsheng Dai et al.
Hui Li et al.
Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming [0.03%]
放射抗性的时空动态变化：通过时空重组解析巨噬细胞驱动的放射保护生态位
Miao Zhang,Xiaolin Zhang,Xueyi Song et al.
Miao Zhang et al.
An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study [0.03%]
基于外泌体的液体活检预测分子残留病以识别II-III期结直肠癌高危患者：清晰研究
Katsuki Miyazaki,Blanca Montcusí,Yuji Morine et al.
Katsuki Miyazaki et al.
Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway [0.03%]
血清淀粉样蛋白A2通过重塑丝氨酸和一碳代谢通路抑制自然杀伤细胞的抗肿瘤免疫从而促进结直肠癌肝转移
Jiamin Zhou,Xigan He,Zhen Xiang et al.
Jiamin Zhou et al.